1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Livzon Pharmaceutical Group Inc.

Livzon Pharmaceutical Group Inc.

1513.HK
Livzon Pharmaceutical Group Inc.HK flagHong Kong Stock Exchange
26.04
HKD
+0.34
- -
28.46BMarket Cap
Livzon Pharmaceutical Group Inc.
1513.HK
(Hong Kong Stock Exchange)

Recent

price

26.04

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
3.22
3.76
4.66
5.47
6.55
7.84
8.77
9.22
9.5
10.01
11.23
12.91
13.49
13.36
12.84
13.49
13.16
Revenue per Share
0.49
0.43
0.52
0.58
0.61
0.74
0.9
4.78
1.16
1.39
1.83
1.9
2.04
2.1
2.24
2.27
2.42
Basic EPS, GAAP
0.35
0.43
-0.2
-0.57
0.06
0.53
1.04
1.1
0.85
1.46
1.62
0.63
1.96
2.61
2.62
2.88
-0.77
Free Cash Flow per Basic Share
0.07
0.04
0.22
0.23
0.24
0.1
0.27
0.23
1.2
0.93
1.17
1.35
1.39
1.71
1.46
1.16
1.81
Dividend per Share
2.06
2.42
2.74
3.14
3.55
4.34
4.86
9.28
9.36
9.98
10.55
11.4
12.15
12.72
13.77
15.29
14.45
Book Value per Share
2.8
3.25
3.39
3.88
4.4
5.25
7.67
11.71
12.14
12.58
13.92
14.31
14.96
14.97
15.39
16.37
15.63
Tangible Book Value per Share
847
841
847
844
846
844
872
926
933
937
937
935
936
930
920
891
897
Basic Weighted Avg Shares
2,727
3,163
3,944
4,619
5,544
6,621
7,652
8,531
8,861
9,385
10,520
12,064
12,630
12,430
11,812
12,020
11,802
Sales/Revenue/Turnover
18.98
14.41
13.35
13.37
11.89
12.33
12.92
14.2
12.47
16.89
22
18.13
17.69
19.56
23.96
23.09
24.79
Operating Margin (%)
121
141
152
169
247
311
362
359
364
385
394
445
652
840
575
574
- -
Depreciation Expense
418
359
442
488
516
623
784
4,429
1,082
1,303
1,715
1,776
1,909
1,954
2,061
2,023
2,171
Net Income, GAAP
15.21
16.27
15.19
16.69
15.09
18.36
17.43
21.61
16.59
15.4
14.39
13.07
16.09
20.36
17.88
15.76
17.35
Effective Tax Rate (%)
15.34
11.36
11.2
10.56
9.31
9.4
10.25
51.91
12.21
13.88
16.3
14.72
15.12
15.72
17.45
16.83
18.4
Profit Margin (%)
1,231
1,387
598
651
497
423
2,660
6,949
7,102
7,580
8,544
7,748
9,591
9,179
8,795
8,898
8,828
Working Capital
67
1
1
550
466
1
1
1
1
- -
370
642
1,986
1,622
1,479
767
1,383
LT Debt
2,639
3,012
3,180
3,605
4,082
4,810
7,106
11,234
11,750
12,275
13,640
14,311
14,936
14,767
14,906
15,547
14,924
Total Equity
15.59
12
12.6
12.19
11.7
12.8
12.73
9.74
7.19
9.84
13.4
11.56
10.45
10.21
12.17
12.37
12.88
Return on Invested Capital (%)
19.63
14.98
15.41
13.14
12.25
13.57
15.83
62.95
9.78
9.94
10.49
11.94
12.67
12.77
10.99
9.34
11.08
Return on Capital (%)
26.53
19.02
20.28
19.63
18.26
18.68
19.85
69.05
12.5
14.41
17.83
17.29
17.34
16.84
16.82
15.39
17.57
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
2,504
2,410
2,237
LT Borrowings
1,466
1,433
1,368
LT Finance Leases
13
15
15
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
911
911
904
Market Capitalization
24,205
22,249
24,183

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
16,420
16,466
16,238
Cash, Cash Equivalents & STI
10,917
10,899
10,611
Accounts Receivable, Net
1,936
2,001
2,301
Inventories
1,998
1,900
1,715
Total Current Liabilities
7,625
7,235
7,410
Payables & Accruals
- -
- -
- -
ST Debt
2,504
2,410
2,237
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
13.94%
2.68%
4.3%
Free Cash Flow
36.16%
37.31%
6.73%
Net Income, GAAP
48.41%
3.41%
-1.84%
Sales/Revenue/Turnover
6.35%
2.91%
1.76%
Total Cash Common Dividend
59.44%
0.27%
-22.93%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3,243
3,040
2,799
2,731
11,812
2025
3,181
3,091
2,904
- -
12,020
2026
2,871
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.65
- -
- -
- -
2.24
2025
0.71
- -
- -
- -
2.27
2026
0.65
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
- -
- -
- -
1.46
2025
0.01
- -
- -
- -
1.16
2026
0.02
- -
- -
- -
- -
Similar Companies
Alkem Laboratories Limited (ALKEM.NS)
Nippon Shinyaku Co., Ltd. (NPNKF)
SugarBud Craft Growers Corp. (SBUDF)
THC Biomed Intl Ltd. (THC.CN)
Krebs Biochemicals & Industries Limited (KREBSBIO.BO)
Sakar Healthcare Limited (SAKAR.NS)
Business
Livzon Pharmaceutical Group Inc. is a comprehensive pharmaceutical company primarily engaged in the research, development, manufacturing, and distribution of pharmaceutical products. Founded in 1985 and headquartered in Zhuhai, China, the company offers a diverse portfolio including chemical drugs, biological drugs, traditional Chinese medicines, and in vitro diagnostics. Its main product categories encompass gastrointestinal drugs such as Ilaprazole enteric coated tablets and Laprazole sodium for injection; reproductive endocrinology products like Leuprorelin Acetate Microspheres and Urofollitropin injection; central nervous system drugs including Perospirone hydrochloride tablets for schizophrenia; and immune and antiviral products such as Tocilizumab injection for rheumatoid arthritis and recombinant SARS-CoV-2 fusion protein vaccine. Livzon also supplies diagnostic kits for autoimmune diseases, HIV, tuberculosis, and mycoplasma pneumonia. Its therapeutic focus includes digestive, cardiovascular, neurological, reproductive, oncological, and infectious diseases. In recent strategic developments, Livzon acquired a 64.81% controlling stake in Vietnam’s Imexpharm Pharmaceutical Joint Stock Company for approximately USD 220.7 million, marking a significant expansion into the international market and supporting its global growth ambitions. The acquisition, financed internally, positions Livzon as Imexpharm's largest shareholder, facilitating deeper penetration into Southeast Asia’s pharmaceutical market. Alongside this, Livzon has strengthened its corporate governance framework by establishing a new Remuneration and Assessment Committee focused on compliance with Hong Kong and Shenzhen listing regulations, enhancing transparency and executive compensation oversight. Livzon Pharmaceutical operates predominantly in China with expanding geographic presence in Southeast Asia through its recent acquisition. The company maintains production of over 400 therapeutic products covering gastrointestinal, anti-infectious, cardiovascular, oncology, immunomodulatory, and neurological fields. It is publicly listed on the Hong Kong and Shenzhen stock exchanges and continues to innovate with blockbuster drugs and complex formulations. Operational updates in the past year reflect solid revenue growth projections fueled by expanded product lines and strategic alliances. These developments reinforce Livzon’s position as a leading integrated pharmaceutical group with a comprehensive product range and growing international footprint.